In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pathway Therapeutics Ltd.

Latest From Pathway Therapeutics Ltd.

MyoKardia appoints Mark Perry to board

MyoKardia, a company focused on developing innovative heart disease therapeutics, has appointed Mark Perry to its board of directors. Mr Perry currently serves as chair of the Pathway Therapeutics board and a director of Nvidia Corporation. Between 1994 and 2007 he worked at Gilead Sciences in roles including CFO and executive vice-president of operations.

Deals Shaping The Medical Industry, October 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August through September 2013.

BioPharmaceutical Medical Device

2011 Scrip Asia 100 - Asia life science-focused VC firms

Asia life science-focused VC firms*


Trans-Tasman chooses pharma for first investment

A new joint Australia/New Zealand fund to support the commercialisation of intellectual property deriving from academic research has made its first investment, in an oncology therapeutics venture.

Cancer New Zealand
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals